Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIT-ANDRE: RNA Editing as a Biomarker of Antidepressant Response
NCT07266545Phase 4Recruiting
- Sponsor
- Mayo Clinic
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vortioxetine and cariprazine in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by Mayo Clinic. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at Week 16. Started Feb 2026; status: recruiting.
02
Drugs
vortioxetinecariprazine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT07266545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266545.